December 11th 2013, Oslo Cancer Cluster, Oslo Medtech and Nansen Neuroscience Network launched a proposal for a new financing mechanism to stimulate innovation from the health- and biotech industry.
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 313 entries.
Entries by oslocancer
Oslo Cancer Cluster member Bayer HealthCare announced Monday December 9th that they just received the marketing approval for Xofigo® (radium Ra 223 dichloride) by the Norwegian Medicines Agency. The approval came approximately one month after the European Commission granted marketing authorization in the EU for Xofigo® on November 15 2013.
Oslo Cancer Cluster member Lytix Biopharma AS has completed a successful issue that was subscribed shares of over 50 million NOK.
Horizon 2020 is the new European Framework Program for Research and Innovation. Oslo Cancer Cluster encourage our members to take a closer look at the possibilities Horizon 2020 represents for funding R&D oncology projects and also taking part in international networks.
Inven2 grants exclusive worldwide license to its epidermal growth factor receptor (EGFR) inhibitors patent portfolio to Merck. Researchers and clinicians at Sørlandet Hospital have discovered that the EGFR inhibitors may play a vital role as a pain reliever for so called neuropathic pain.
Algeta and Bayer have received marketing authorisation from the European Commission for Xofigo® for the treatment of prostate cancer patients with bone metastases.
Three Oslo Cancer Cluster SME`s emerged as the winners of the Immuno-Oncology Innovation Call. Oncoinvent was as a clear number one of the 10 applications received.
The 2013 year’s grant to cancer research in Norway, 160 million NOK (EUR 20 M) is the largest grant the Norwegian Cancer Society has ever given.
The new government of Norway has launched their political platform. Oslo Cancer Cluster have reviewed the political platform document. We are overall very pleased with the initiatives that concerns research, knowledge, education, business and R&D.
Oslo Cancer Cluster was the proud host of a press conference in early October, where two of the Nordic region’s largest governmental venture investors Investinor and Industrifonden announced their NOK million 90 investment in Swedish biotech Pharmalink.
Life Technologies Corporation has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer. Both Novartis and Life Technologies are member of Oslo Cancer Cluster.
Now in its fourth year as a member of the Oslo Cancer Cluster, Ockham Oncology unveils its stronger global oncology expertise, as a fully integrated, pure oncology-focused international partner.
Oslo Cancer Cluster, the Norwegian Cancer Society and the Association of the Pharmaceutical Industry in Norway join forces in pushing for a new cancer drugs fund. The purpose of the fund is to ensure equal and quicker access to new approved cancer drugs in Norway. A cancer drugs fund would cover the costs of […]
Contact Team >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.